Persistent cortisol non-suppression after clinical recovery predicts symptomatic relapse in unipolar depression by Charles, Gerard A. et al.




Persistent cortisol non-suppression after clinical recovery 
predicts symptomatic relapse in unipolar depression 
G&ard A. Charles I, Michel Schittecatte ‘, A. John Rush 2, Michael Panzer 3 and 
Jean Wilmotte ’ 
’ Centre Hospituher Vincent Van Gogh. Rue de I’H6pital55, B-6030 Charleroi. Belgrum. .’ Unioersit~ of Texas Health Science Center, 
Department of Psychiatcv, DalIus, TX 75235, U.S.A. and -’ Universgv of Michigan Department of P.~ychirrt~v. 
Ann Arbor, MI 48109, U.S.A. 
(Received 17 June 1988) 
(Revision received 21 March 1989) 
(Accepted 11 April 1989) 
Summary 
We assessed the length and the quality of remission of 13 unipolar endogenous depressed patients, DST 
non-suppressors before treatment, in a 2-year prospective study. During this period, we recorded stressful 
life events. Persistent dexamethasone non-suppression, after treatment and complete clinical recovery, 
correlated highly with early clinical relapse. All six non-normalizers but only one normalizer were 
rehospitalized within the following 2 years for a major depressive relapse. Persistent DST non-suppression 
was unrelated to any impact of drug discontinuation, the occurrence of stressful life events or the length of 
illness-free intervals in the patient’s prior course of illness. Persistent DST non-suppression appears to 
have significant prognostic value. 
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Introduction 
Early escape of plasma cortisol the day follow- 
ing a l-mg dexamethasone dose at midnight ap- 
parently identifies endogenous depression (melan- 
cholia) with a sensitivity ranging from 35 to 60% 
(Carroll, 1982). Dexamethasone non-suppression 
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seems to be state-dependent as the dexamethasone 
suppression test (DST) normalizes in over 70% of 
the DST non-suppressors with clinical recovery 
and DST normalization usually occurs before 
complete symptomatic remission (Greden et al., 
1983). Through different depressive episodes, the 
DST remains comparable for any single patient 
(Grunhaus et al., 1983). Further reversion of dexa- 
methasone suppression to non-suppression ap- 
parently precedes clinical relapse by l-3 weeks 
(Holsboer et al., 1983). Several studies have pos- 
tulated that persistent DST non-suppression in 
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High rate of sui- 
tide (30%) among 
non-normalizers 
8 5 No info 
25 4 6 
8 2 No info ECT 
11 9 6 
9 2 No info ECT 
31 8 12 
3 2 No info ECT 
3 2 6 
9 4 No info 
20 6 6 
7 5 No info ECT 
15 1 3 
a Delay indicates the delay of relapse (in weeks) for the non-normalizers (1) and the delay of survey (in months) for the normalizers 
(2). 
h No info indicates that these non-normalizers relapsed at unspecified times after discharge, within the same survey period as for 
normalizers. 
clinically improved patients indicates a poor prog- 
nosis relative to normalization of DST status. 
These and other studies are summarized in Table 
1. 
We selected only patients who were DST non- 
suppressors before treatment. Follow-up data for 
both normalizers and non-normalizers were re- 
quired for a study to be included. We disregarded 
cases whose clinical recovery was insufficient to 
allow discharge as they might better be regarded 
as treatment failures. Several studies concur that 
failure to normalize the DST with clinical recovery 
is predictive of a higher risk of early relapse. 
Greden et al. (1980) found that among pharmaco- 
logically treated patients, all four non-normalizers 
but none of eight normalizers had a poor outcome 
at follow-up. 
A number of groups have used concomitant 
electroconvulsive therapy (ECT) and phar- 
macotherapy. Schweitzer and collaborators (1987) 
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obtained similar results, with five of seven per- 
sistent non-suppressors but only one of 15 normal- 
izers relapsing. In contrast, Lipman et al. (1986) 
found the opposite: nine of 11 normalizers com- 
pared to two of eight persistent non-suppressors 
were treatment failures within 6 months. A paper 
by Katona and others (1987) revealed no predic- 
tive value one way or the other for subsequent 
relapse. 
Overall, 13 studies have followed 384 initial 
DST non-suppressors, among whom 153 (40.3%) 
failed to normalize the DST with clinical improve- 
ment. Of the 231 who did normalize their DST, 
only 46 (19.9%) relapsed compared to 59 of 156 
(31.8%) who failed to normalize their DST (Fisher’s 
exact test: P < 0.0001). Relapse occurred between 
0.5 and 18 months post discharge. 
Occurrence of stressful life events has been 
implicated in relapse of depression. Paykel (1979) 
found that repetitive stress can exacerbate endoge- 
nous depression. Lloyd (1980) reviewed eight con- 
trolled studies, seven of which found a significant 
correlation between life events (mostly loss of 
immediate family members or close friends) and 
subsequent depression. More recently, however, 
Brown et al. (1987) used a combination of con- 
textual methods and ‘matching’ of events to char- 
acteristics of the 400 women in the study to dem- 
onstrate ‘ the major importance of long-term severe 
threatening life events in provoking caseness of 
depression’. 
The present study evaluated clinical factors that 
might relate to continuing DST non-suppression 
following clinical recovery, including occurrence 
of stressful events, type of treatment, and a num- 
ber of descriptive patient characteristics. Per- 
sistent non-suppression vs. normalization and 
medication status were tested as predictors for 
clinical relapse. We included only endogenous de- 
pressives with a prior history of complete clinical 
remission between previous episodes, or patients 
who were suffering their first depressive episode. 
We excluded chronic depression. 
Patients and methods 
Patients 
From October 1980 through December 1981, 
we identified 13 inpatients from roughly 500 inpa- 
tients consecutively admitted to the Department 
of Psychiatry, Civil Hospital, Charleroi (Belgium). 
The patients completed a follow-up period consist- 
ing of 2 years on a monthly basis. All patients met 
Research Diagnostic Criteria (RDC) (Spitzer et 
al., 1978) for primary major unipolar depression, 
definite endogenous subtype, as well as DSM-III 
criteria for major depression with melancholic fea- 
tures (American Psychiatric Association, 1980). 
Bipolar patients were excluded. We also excluded 
patients with alcoholism, medical disorders, obes- 
ity, and those taking oral contraceptives or drugs 
that induce liver enzymes (Carroll et al., 1981). 
Clinical assessment was based on the SADS-L 
structured interview (Spitzer and Endicott, 1978). 
Nine of the 13 patients suffered from recurrent 
depressive episodes. The mean number of episodes 
was 4.8 (SD = 3.2) and ranged from two to 11 
episodes. Only DST non-suppressors, i.e., patients 
with 4 p.m. plasma cortisol of 5 pg/dl or greater, 
as measured 17 h after the ingestion of 1 mg 
dexamethasone, were included (Charles et al., 
1981). Written informed consent was obtained 
from patients. 
Methods 
Patients were hospitalized for at least 10 days 
and were drug-free for at least 15 days before the 
first I-mg overnight DST (time 1). The DST meth- 
odology and cortisol determinations have been 
previously described (Charles et al., 1981). The 
severity of depressive symptoms was assessed with 
the 21-item Hamilton Rating Scale for depression 
(HRS) (Hamilton, 1960). Before discharge, pa- 
tients received a second DST (time 2) as described 
above, while taking either amitriptyline or de- 
sipramine. 
Patients received either amitriptyline or de- 
sipramine (not randomized). Treatment began 
after the initial assessment (time 1) procedures 
were completed. Treatment was selected and con- 
ducted independent of and blind to these ratings. 
All patients and treating physicians were blind to 
DST and rating scales results. The physicians 
judged symptomatic recovery and made decisions 
to discharge based only on their own clinical 
judgment. However, clinical improvement that was 
sufficient to merit discharge was routinely associ- 
ated with at least a 50% reduction in the initial 
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HRS score and in all cases with an end of 
hospitalization HRS score of 12 or less. The medi- 
cation ingested was recorded for the survey period, 
but antidepressant plasma levels were not mea- 
sured. Antidepressant medications only are re- 
ported here. None of the other drugs taken by the 
patients are known to influence the DST (Carroll 
et al., 1981; Amsterdam et al., 1981) and none was 
taken later than 1 month prior to time 3 evalua- 
tion. 
Relapse was defined as a new episode of major 
depression, requiring readmission. Between 3 and 
18 months following hospital discharge, seven pa- 
tients were thus rehospitalized. A second psychi- 
atric evaluation and, after a 15-day drug-free 
wash-out period, a third DST (time 3) were con- 
ducted. Within 2 years, the remaining six patients, 
without relapse, underwent a third DST and HRS. 
Life events were assessed at time 3. This infor- 
mation was corroborated by the monthly clinical 
interviews by the primary physicians. For the 
period between times 2 and 3, the number of 
stressful events was counted based on the list of 
events (Paykel et al., 1971). Their subjective im- 
portance was assessed according to Monroe’s 
methodology (1982). 
Statistics 
Welch’s t-test (WtT) and paired t-test (PtT) 
were used. Fisher’s exact test (FET) was used for 
the 2 X 2 comparisons in which one of the ex- 
pected values was 5 or less. The chi-square test 
was used for the other categorical comparisons. 
All Ps were 2-tailed. The results are expressed as 
the means, standard deviations and ranges. 
Results 
Table 2 displays the results for the entire sam- 
ple. At the end of the first hospitalization, all 13 
patients were clinically recovered (HRS time 2: 
7.1 (3.4); 3-12) but only seven (54%) normalized 
the DST (i.e., became DST suppressors). The six 
patients who remained non-suppressors at the end 
of hospitalization were rehospitalized within the 
following 2 years for a depressive relapse which 
TABLE 2 
SAMPLE CHARACTERISTICS 
Age/sex No. Inter Time 1 Time 2 Time 3 T2-T3 Treatment No. life T2-LE 















33/F NA NA 
60/F 11 25 
60/M 6 46 
59/F 2 60 
53/F 2 30 

























AMI 3 0 
AMI 3 31 
AM1 5 0 
DMI 6 0 
DMI 10 0 
AM1 12 0 
DMI 9 0 
2.5/8/NA 19 AM1 12 
3.5/8/NA 20 DMI 20 
2.0/11/NA 22 DMI 8 
2.5/8/NA 24 AM1 24 
4.0/10/NA 25 AM1 10 



















No. epi indicates number of previous episodes 
Inter epi indicates mean duration in months between previous episodes 
Treatment: DMI indicates desipramine; AM1 indicates amitriptyline. 
Duration indicates duration in months between time 2 and end of antidepressant treatment. 
No. life events indicates number counted following Paykel et al. (1971). 
T2-LE indicates months between time 2 and occurrence of life event. 
Time 3/month indicates month of relapse. 
* Relapses; NA, not applicable; CORT, 4 p.m. post-dexamethasone cortisol (pg/dl); HRS, 21-item Hamilton Rating Scale score. 
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once again met RDC for major depression, endog- 
enous subtype. Out of the seven DST normalizers 
at time 2, only one was rehospitalized (after 12 
months). DST non-suppression in this patient at 
time 3 (5.5 pgg/dl) was comparable to his post- 
dexamethasone cortisol at time 1 (5.0 pgg/dl). The 
difference in the number of relapsing patients 
among the seven normalizers (n = 1) and the six 
non-normalizers (n = 6) reached a level of P = 
0.005 (FET). For the seven relapsers, HRS at time 
3 (32.8 (5.4); 25539) did not differ from HRS at 
time 1 (32.7 (9.7); 24-42) (PtT = 0.03; df = 6; 
P = NS). Six of the seven who relapsed were still 
DST non-suppressors at the time of relapse 
(cortisol at time 3: 6.8 (1.8); 5.0-9.5 pg/dl), while 
one of the relapsers was a suppressor (cortisol at 
time 3: 3.5 pgg/dl). There were no significant 
differences between the normalizers and non-nor- 
malizers at time 2 for type of treatment (five of 
seven normalizers and three of six non-normal- 
izers received amitriptyline; FET P = 0.528). The 
two populations were comparable for age (48.9 
(11.9) for normalizers vs. 52.2 (13.6) for non-nor- 
malizers; WtT = 0.46; P = NS), sex ratio (six of 
seven normalizers and four of six non-normalizers 
were female; FET P = 0.552) and age at the onset 
of illness (normalizers 37.5 (6.9) vs. non-normal- 
izers 42.0 (7.0); WtT = 1.1; P = NS). The HRS 
scores at time 2 for the six non-normalizers (8.00 
(3.03)) did not significantly differ from those of 
the normalizers (6.42 (3.77)) (t = 0.831; df = 10; 
P = NS). There were no differences between the 
relapsers and non-relapsers at time 1 either in 
post-dexamethasone cortisol levels (relapsers 6.9 
(1.3) vs. non-relapsers 10.0 (3.5); t = 2.19; df = 11; 
P = 0.051) or in HRS scores (relapsers 32.7 (9.7) 
vs. non-relapsers 33.5 (8.4); t = 0.15; df = 11; P = 
0.881). For the patients suffering from recurrent 
illness (five normalizers and four non-normalizers), 
no difference was observed in the number of 
previous episodes (normalizers 4.6 (4.0) vs. non- 
normalizers 5.0 (2.6); WtT = 0.18; P = NS) or in 
the mean time between episodes (normalizers 38.2 
(14.0) months vs. non-normalizers 31.5 (12.7); 
WtT = 0.73; P = NS). 
Among the seven normalizers, five experienced 
stressful events within the following 2 years (2-22 
months) before the time 3 re-evaluation, although 
none of these five relapsed. The one normalizer 
who did relapse did not report any stressful events. 
Only one of the six non-normalizers who relapsed 
reported a stressful event, which occurred 1 month 
before relapse. 
The difference between the two groups in the 
number of patients who experienced any kind of 
stressful life events did not reach statistical signifi- 
cance (five of seven normalizers vs. one of six 
non-normalizers; FET P = 0.103). The low inci- 
dence of reported life stresses and the sample size 
preclude discussion of any relationship between 
life stresses and clinical relapse. However, in this 
sample, stressful life events do not relate to the 
subsequent course of illness. 
Medication status did not seem to influence 
relapse. No significant difference between re- 
lapsers and non-relapsers with regard to medica- 
tion status at time 3 was found (relapsers: six of 
seven on drug compared to non-relapsers: two of 
six; FET P = 0.3099). Four of the six normalizers 
stopped taking medication 7-20 months before 
time 3 evaluation, and none relapsed. The two 
normalizers who were still taking their drug at 
time 3 were withdrawn for 15 days in order to 
perform the DST at time 3, and neither exhibited 
any recurrence of symptomatology. One patient 
who failed to normalize his DST in the meanwhile 
stopped taking medication 9 months before re- 
lapse. Five non-normalizers and one normalizer 
were still on medication when they relapsed. 
Discussion 
These data indicate that clinical relapse over 
the short term (3-18 months) more often occurred 
in those DST non-suppressors who failed to nor- 
malize their DST at the time of clinical recovery 
than in those who normalized their DST. The time 
between hospital discharge and relapse was shorter 
than the usual euthymic time period between pre- 
vious episodes. Stressful life events did not seem 
to account for relapse. A number of patients who 
normalized their DST at time 2 experienced sig- 
nificant and in some cases severe life stresses but 
failed to relapse. The state-dependent relationship 
between persistent non-suppression and likelihood 
of relapse, as well as the relationship between 
suppression and a more durable recovery, is indi- 
cated by these data. Finally, as previously re- 
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ported (Grunhaus et al., 1983) patients’ DST 
statuses are reproducible across different episodes 
of depression. That is, a patient who is a non-sup- 
pressor in one episode is likely to fail to suppress 
in the following episode. 
As stated above, our finding that persistent 
non-suppression is a risk factor for early relapse 
supports the results of Schweitzer et al. (1987). 
Other recent reports, however, find no value no 
DST normalization vs. persistent non-suppression 
for predicting relapse. Katona et al. (1987) found 
no significant difference between these two groups 
of patients treated with ECT and medication. 
Mendlewicz et al. (1986) had similar results. Pese- 
low et al. (1987) had a non-significant trend (six of 
20 normalizers relapsed vs. four of nine persistent 
non-suppressors). Varying criteria for recovery and 
relapse may partially account for the contradic- 
tion. While our patients showed a decrease in 
HRS scores to 12 or less with treatment which 
represented a 50% or more improvement, Katona 
et al. required a final HRS of 6 or less, and 
Mendlewicz et al. required an HRS improvement 
of 70% or more. If Schweitzer et al. (1987) are 
correct in suggesting that persistent non-suppres- 
sors may have persistent hypothalamic-pituitary- 
adrenal (HPA) axis dysfunction despite clinical 
improvement, then more stringent improvement 
criteria might exclude some partially treated cases, 
thus making the two groups appear more similar 
in prognosis. Relapse criteria could also help ex- 
plain the different results. Mendlewicz et al. de- 
fined relapse as depression meeting RDC criteria 
for major depressive disorder. We considered only 
depression necessitating readmission. It is possible 
that the two patient groups differ prognostically 
only in regard to more severe symptoms; this 
would explain why our study using stricter relapse 
criteria achieved significance while others may 
not. 
Neither of these could explain the results of 
Lipman et al. (1986), who found that persistent 
non-suppressors had a better prognosis at 6-month 
follow-up. In that retrospective study, however, 
the authors did not know what treatment the 
patients received between discharge and relapse. 
Similarly, Coryell and Zimmerman (1983) had re- 
sults contradicting ours in the same way, but did 
not report intervening treatment between dis- 
charge and follow-up. Thus, different treatment 
between suppressors and non-suppressors could 
account for the results of these two studies, while 
we have documented that treatment did not differ 
between our patient groups. We admit, however. 
that we did not measure antidepressant blood 
levels to further verify this. Moreover, we did 
assess the compliance of the patients, followed on 
a regular monthly basis, to their medication. 
One strength of the present study is the follow- 
up period of 2 years, which is longer than most 
others. The use of extended follow-up periods in 
future studies may add to the weight of evidence 
supporting the utility of DST results in predicting 
prognosis. 
Another factor that needs to be considered is 
ECT vs. pharmacological treatment. From studies 
done thus far, no clear pattern is evident regarding 
the effect of treatment modality on predicting 
delayed outcome based on DST results. However, 
two studies (Coppen et al., 1985; Devanand et al., 
1987) show that the DST has different predictive 
values in immediate outcome depending on 
whether ECT or drug therapy was used. This 
needs to be explored in future studies. 
The trend (even non-significant) for the non- 
normalizers to exhibit a slightly higher HRS score 
at recovery (time 2) compared to normalizers goes 
along with observations by Greden et al. (1980) 
and might reflect a persistent dysregulation or 
partial treatment response. The high frequency of 
relapses among the non-normalizers could be ex- 
plained as a consequence of having an illness that 
is poorly or only partially treated with available 
antidepressant techniques. Antidepressant drugs 
might increase motor activity and lead to signifi- 
cant clinical improvement, but fail to fully convert 
the underlying pathophysiology of the illness. It is 
understandable that a partially effective antide- 
pressant drug (too short-timed, infratherapeutic 
plasma levels, low local brain concentrations or 
not specific enough) might increase motor activity 
without modifying the endocrine perturbances 
(e.g., DST non-suppression) which could second- 
arily lead to clinical relapse (Holsboer et al., 1983). 
A clinical example of this hypothesized dissocia- 
tion between clinical and HPA status is to be 
found at the beginning of most antidepressant 
drug therapy. Patients usually show psychomotor 
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improvement within the first 5 days (Ey et al., 
1974). However, the DST normalizes around 2-3 
weeks, just before internal feelings and the general 
mood improve (Greden et al., 1983). 
The implication is that persistent non-suppres- 
sors need to be treated more aggressively. This 
would be at odds with the results of Goldberg 
(1980) and the present study that discontinuation 
of treatment does not precipitate relapse. Our 
normalizers did not relapse despite discontinua- 
tion, while the persistent non-suppressors relapsed 
in the face of ongoing treatment. However, the 
possibility certainly exists that better maintenance 
treatment (antidepressant blood levels, different 
drug choice or modalities) in future studies could 
show. that long-term treatment of persistent non- 
suppressors prevents relapse while treatment of 
normalizers could be more safely discontinued. 
The other goal of this study was to examine the 
possible role of life events in precipitating relapse. 
In our sample, stressful events did not precipitate 
a recurrence of major depressive symptoms nor 
did they reverse a normalized DST. This agrees 
with Saleem’s observation (1984) that DST non- 
suppression in depression is more related to an 
endogenous substrate for the illness than to anxiety 
or stress. Lesser and co-workers (1984) were un- 
able to discriminate situational depression from 
depression without precipitating events by DST 
non-suppression in endogenously ill patients. 
Mendlewicz et al. (1986) found no correlation 
between relapse and life events (except bereave- 
ment among immediate family and close friends) 
among 24 unipolar and 16 bipolar endogenous 
patients. Four of 10 relapsers and four of 30 
non-relapsers experienced life events. Certainly, 
methodological issues assume major importance in 
studying life events and depression. 
Lack of social support could be a bias in study- 
ing relapse in depressive patients. In our sample, 
we retrospectively check that no patient lost any 
social support during the survey period. 
Another factor that might be responsible for 
abnormal DST results is the altered dexametha- 
sone kinetics in depressed patients (Maguire et al., 
1987). 
Lowy and Meltzer (1987) recently stated that 
‘simultaneous measurement of serum dexametha- 
sone and cortisol levels appears to be necessary 
for the appropriate evaluation of DST results’. 
The best way to assess the very low dexametha- 
sone concentration during a DST seems to be a 
microliquid chromatography-mass spectrometry 
method. This is not yet available on a clinical 
routine basis. However, DST has been shown to 
be reproducible within a single episode (Charles et 
al., 1982) and across hospitalizations (Grunhaus et 
al., 1983). Moreover, Carson et al. (1988) demon- 
strated that patients with major depressive dis- 
orders had less suppressibility of cortisol to the 
same plasma dexamethasone concentrations than 
controls. Differences in dexamethasone metabo- 
lism might explain different DST statuses in major 
depressive disorders. A genuine reduced sensitivity 
of cortisol to dexamethasone still points to an 
abnormality of the feedback mechanism of the 
HPA in some depressed patients. The normaliza- 
tion after treatment of this abnormality and the 
DST reversion back to suppression might lead to a 
sustained recovery in those normalizers, whereas 
the non-normalizers might keep a higher cortisol/ 
dexamethasone ratio and reach a less complete 
recovery. 
This study provides preliminary results. Repli- 
cation with a longer survey period to better account 
for the spontaneous course of illness, with assess- 
ment of antidepressant and dexamethasone plasma 
levels and with a greater number of endogenous 
patients, as well as a control group of reactive 
depressives, is needed. However, the present find- 
ings argue for the prognostic value of persistent 
DST non-suppression unrelated to any impact of 
stressful life events. 
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